Table 2.
Response and outcome.
| Parameter |
All patients n = 715 |
Therapy groups | p-value | ||
|---|---|---|---|---|---|
|
SC n = 146 |
CS n = 325 |
IT n = 244 |
|||
| Response | |||||
| CR | 473 (66.2) | 54 (37.0) | 266 (81.8) | 153 (62.7) | <0.001 |
| PR | 106 (14.8) | 30 (20.5) | 31 (9.5) | 45 (18.4) | 0.001 |
| NR | 78 (10.9) | 44 (30.1) | 15 (4.6) | 19 (7.8) | <0.001 |
| ESRD | 57 (8.0) | 18 (12.3) | 13 (4.0) | 26 (10.7) | 0.001 |
| Death | 1 (0.1) | 0 (0.0) | 0 (0.0) | 1 (0.4) | 1.000 |
| CKD 1 | |||||
| CR | 287 (76.1) | 37 (45.7) | 178 (90.8) | 72 (72.0) | <0.001 |
| PR | 51 (13.5) | 23 (28.4) | 12 (6.1) | 16 (16.0) | <0.001 |
| NR | 30 (8.0) | 19 (23.5) | 4 (2.0) | 7 (7.0) | <0.001 |
| ESRD | 9 (2.4) | 2 (2.5) | 2 (1.0) | 5 (5.0) | 0.090 |
| CKD 2 | |||||
| CR | 142 (61.5) | 16 (33.3) | 71 (77.2) | 55 (60.4) | <0.001 |
| PR | 37 (16.0) | 5 (10.4) | 12 (13.0) | 20 (22.0) | 0.129 |
| NR | 28 (12.1) | 17 (35.4) | 6 (6.5) | 5 (5.5) | <0.001 |
| ESRD | 24 (10.4) | 10 (20.8) | 3 (3.3) | 11 (12.1) | 0.003 |
| CKD 3a | |||||
| CR | 44 (41.1) | 1 (5.9) | 17 (45.9) | 26 (49.1) | 0.005 |
| PR | 18 (16.8) | 2 (11.8) | 7 (18.9) | 9 (17.0) | 0.940 |
| NR | 20 (18.7) | 8 (47.1) | 5 (13.5) | 7 (13.2) | 0.010 |
| ESRD | 24 (22.4) | 6 (35.3) | 8 (21.6) | 10 (18.9) | 0.363 |
| Death | 1 (0.9) | 0 (0.0) | 0 (0.0) | 1 (1.9) | 1.000 |
| Outcome | |||||
| Combined end point | 64 (9.0) | 21 (14.4) | 15 (4.6) | 28 (11.5) | 0.001 |
| 50% decline in eGFR | 56 (7.8) | 18 (12.3) | 14 (4.3) | 24 (9.8) | 0.004 |
| ESRD | 57 (8.0) | 18 (12.3) | 13 (4.0) | 26 (10.7) | 0.001 |
| Death | 1 (0.1) | 0 (0) | 0 (0) | 1 (0.4) | 1.000 |
Data presented as number (percentage). CKD, chronic kidney disease; CR, complete remission; eGFR, estimated glomerular filtration rate; PR, partial remission; NR, no response; ESRD, end-stage renal disease; SC, supportive care group; CS, corticosteroids; IT, immunosuppressive therapy.